BioSpace News Archive

Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the third quarter 2022, are summarised below. Exscientia will host a conference call today, November 15, at 1:30 p.m. GMT / 8:30 a.m. ET.

Alzamend Neuro, Inc. today announced that CEO Stephan Jackman will be interviewed on the Fox Business Network news channel on Wednesday, November 16, 2022.

The 2022 “State of Lung Cancer” report shows that only 5.8% of eligible Americans have been screened for lung cancer, and some states have screening rates as low as 1%.

Nona Biosciences announced that the Company is attending the 14th Protein and Antibody Engineering Summit in Barcelona, Spain, November 14-16, 2022.

Tyber Medical LLC, the global, leading private-label medical device provider for major orthopedic trauma, extremity, and spine companies, has been awarded a U.S. Food and Drug Administration (FDA) 510(k) clearance for its new NiTy+ One-Shot™ Staple Fixation System.

RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).

Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, announced the close of its $107 million Series C financing.

Kineta, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) to evaluate its VISTA blocking immunotherapy, KVA12123 (formerly referred to as KVA12.1), as a potential treatment for patients with advanced solid tumors.

Affimed N.V. today reported financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate progress.

Freeline Therapeutics Holdings plc reported financial results for the third quarter of 2022 and announced its decisions to sell its CMC-focused subsidiary in Germany to Ascend Gene and Cell Therapies Ltd., streamline its organization to increase efficiency and strengthen its financial position, and prioritize the development of FLT201 in Gaucher disease and FLT190 in Fabry disease.